Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b

European Journal of Cancer

Volumn 39, Issue 11, 2003, Pages 1632-1641

  Lee, S J ^a,b   Sakurai, H ^a   Oshima, K ^c   Kim, S H ^b   Saiki, I ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Kyung Hee University   (South Korea)

^c Daiichi Fine Chemical Co Ltd   (Japan)

Author keywords

Angiogenesis; Lymph node metastasis; MMP inhibitor

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; TN 6B; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LIVER SINUSOID; LYMPH NODE METASTASIS; MELANOMA; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; ZYMOGRAPHY;

EID: 0037632207     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00375-7     Document Type: Article

References (37)

1. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 340:1992;145-146.
2. Ishikura H., Kondo K., Miyoshi T.et al. Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line. Clin. Cancer Res. 7:2001;4202-4208.
3. Folkman J. Tumor angiogenesis. therapeutic implications N. Engl. J. Med. 285:1971;1182-1186.
4. Zetter B.R. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49:1998;407-424.
5. Woodhouse E.C., Chuaqui R.F., Liotta L.A. General mechanisms of metastasis. Cancer. 80:1997;1529-1537.
6. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer. trials and tribulations Science. 295:2002;2387-2392.
7. Stetler-Stevenson W.G. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am. J. Pathol. 148:1996;1345-1350.
8. Naglich J.G., Jure-Kunkel M., Gupta E.et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 61:2001;8480-8485.
9. Rasmussen H.S., McCann P.P. Matrix metalloproteinase inhibition as a novel anticancer strategy. a review with special focus on batimastat and marimastat Pharmacol. Ther. 75:1997;69-75.
10. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition. a review of anti-tumour activity Ann. Oncol. 6:1995;967-974.
11. Talbot D.C., Brown P.D. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur. J. Cancer. 32A:1996;2528-2533.
12. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93:2001;178-193.
13. Belloni P.N., Carney D.H., Nicolson G.L. Organ-derived microvessel endothelial cells exhibit differential responsiveness to thrombin and other growth factors. Microvasc. Res. 43:1992;20-45.
14. Yamamoto M., Tsujishita H., Hori N.et al. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors. an examination of the subsite pocket J. Med. Chem. 41:1998;1209-1217.
15. Knight C.G., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 296:1992;263-266.
16. Aoki T., Yonezawa K., Ohuchi E.et al. Two-step sandwich enzyme immunoassay using monoclonal antibodies for detection of soluble and membrane-associated human membrane type 1-matrix metalloproteinase. J. Immunoassay Immunochem. 23:2002;49-68.
17. Itano T., Itano R., Penniston J.T. Determination of inorganic phosphate in the presence of nonionic detergents. a modified isobutanol-benzene extraction method Anal. Biochem. 101:1980;196-199.
18. Brown P.D., Levy A.T., Margulies I.M., Liotta L.A., Stetler-Stevenson W.G. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50:1990;6184-6191.
19. Saiki I., Murata J., Watanabe K., Fujii H., Abe F., Azuma I. Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro. Jpn. J. Cancer Res. 80:1989;873-878.
20. Saito K., Oku T., Ata N., Miyashiro H., Hattori M., Saiki I. A modified and convenient method for assessing tumor cell invasion and migration and its application to screening for inhibitors. Biol. Pharm. Bull. 20:1997;345-348.
21. Murata J., Saiki I., Makabe T., Tsuta Y., Tokura S., Azuma I. Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res. 51:1991;22-26.
22. Doki Y., Murakami K., Yamaura T., Sugiyama S., Misaki T., Saiki I. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br. J. Cancer. 79:1999;1121-1126.
23. Vu T.H., Shipley J.M., Bergers G.et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:1998;411-422.
24. Lozonschi L., Sunamura M., Kobari M., Egawa S., Ding L., Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res. 59:1999;1252-1258.
25. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 10:2000;415-433.
26. Eliceiri B.P., Cheresh D.A. Adhesion events in angiogenesis. Curr. Opin. Cell Biol. 13:2001;563-568.
27. Chen W.T., Wang J.Y. Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann. New York Acad. Sci. 878:1999;361-371.
28. De Leeuw W.J., Berx G., Vos C.B.et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J. Pathol. 183:1997;404-411.
29. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13:1999;35-48.
30. Saaristo A., Karpanen T., Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 19:2000;6122-6129.
31. Wakisaka N., Wen Q.H., Yoshizaki T.et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope. 109:1999;810-814.
32. Mullins D.E., Rohrlich S.T. The role of proteinases in cellular invasiveness. Biochim. Biophys. Acta. 695:1983;177-214.
33. Kubota Y., Kleinman H.K., Martin G.R., Lawley T.J. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 107:1988;1589-1598.
34. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis. an imbalance of positive and negative regulation Cell. 64:1991;327-336.
35. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1-8.
36. Hirota J., Yoneda K., Osaki T. Basement membrane type IV collagen in oral squamous cell carcinoma. Head Neck. 12:1990;400-405.
37. Pitzel L., Ludemann S., Wuttke W. Secretion and gene expression of metalloproteinases and gene expression of their inhibitors in porcine corpora lutea at different stages of the luteal phase. Biol. Reprod. 62:2000;1121-1127.